Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Pulsed Dose Chemotherapy Plus Pembrolizumab in the First Line Treatment of Recurrent/Metastatic HNSCC

NCT06052839 is registered in ClinicalTrials.gov with Dan Zandberg as lead sponsor.

NCT NCT06052839
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06052839 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Pulsed Dose Chemotherapy Plus Pembrolizumab in the First Line Treatment of Recurrent/Metastatic HNSCC
Lead sponsor
Dan Zandberg
Phase
Phase 2
Overall status
Recruiting
Start date
October 3, 2023
Completion date
December 31, 2027
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent/metastatic head and neck squamous cell carcinoma (r/m hnscc)